OTC · Health care

BioStem Technologies, Inc. (BSEM)

At June 30, 2026 it held $7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Watch BSEM in 60 seconds

Price

$4.05

-2.17% on the day · September 28, 2026

52-week range $2.25 to $8.40

Market cap

$72.3M

What BioStem Technologies, Inc. does

BioStem Technologies, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker BSEM.

Latest SEC filings

What BioStem Technologies, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 18, 2026
IPO registration S-1
September 18, 2026
Material agreement 8-K
August 14, 2026
Securities offering prospectus 424B3
August 13, 2026
Securities offering prospectus 424B3
August 12, 2026
Quarterly results 8-K
August 12, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 28% to $7.9M versus the same quarter last year; diluted EPS -$0.52 versus $0.00.
August 7, 2026
IPO registration (amended) S-1/A
August 7, 2026
Other event 8-K
August 7, 2026
Form SEC STAFF ACTION filing SEC STAFF ACTION
August 4, 2026
Spin-off registration (amended) 10-12B/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 17, 2026. Insider transactions on SEC

Insider trades

What the people running BioStem Technologies, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 12 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
September 17, 2026	Smith-Van Vurst AndrewChief Operating Officer, Director, 10% owner	Exercised options	9,574	-	-	Form 4
September 17, 2026	Matuszewski JasonChief Executive Officer, Director, 10% owner	Exercised options	16,650	-	-	Form 4
September 15, 2026	Fortunato Michael AChief Accounting Officer	Exercised options	4,234	-	-	Form 4
September 15, 2026	Warrington Kenneth Howard JrDirector	Exercised options	1,694	-	-	Form 4
September 15, 2026	Smith-Van Vurst AndrewChief Operating Officer, Director, 10% owner	Exercised options	7,622	-	-	Form 4
September 15, 2026	Poe BrandonChief Financial Officer	Exercised options	1,694	-	-	Form 4
September 15, 2026	Matuszewski JasonChief Executive Officer, Director, 10% owner	Exercised options	8,469	-	-	Form 4
September 9, 2026	Hassett BarryChief Commercial Officer	Exercised options	500	-	-	Form 4
August 27, 2026	Glickman Mark ADirector	Exercised options	7,671	-	-	Form 4
August 27, 2026	Lesser Hannaway RaynaDirector	Exercised options	7,671	-	-	Form 4
August 27, 2026	Warrington Kenneth Howard JrDirector	Exercised options	5,094	-	-	Form 4
August 27, 2026	Ungrodt JodiDirector	Exercised options	5,647	-	-	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BSEM

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

9 insiders reported holding 3,035,655 shares in total, about $12.3M at the last price.

Holder	Shares	As of
Smith-Van Vurst AndrewChief Operating Officer, Director, 10% owner	1,539,809	September 17, 2026
Matuszewski JasonChief Executive Officer, Director, 10% owner	1,303,552	September 17, 2026
Fortunato Michael AChief Accounting Officer	68,664	September 15, 2026
Poe BrandonChief Financial Officer	58,062	September 15, 2026
Warrington Kenneth Howard JrDirector	33,928	September 15, 2026
Ungrodt JodiDirector	11,295	August 27, 2026
Lesser Hannaway RaynaDirector	7,671	August 27, 2026
Glickman Mark ADirector	7,671	August 27, 2026
Hassett BarryChief Commercial Officer	5,003	September 9, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BSEM

What does BioStem Technologies, Inc. do?

BioStem Technologies, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker BSEM.

When did BioStem Technologies, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from September 18, 2026.

Similar companies

AMGN

Amgen Inc

GILD

Gilead Sciences, Inc.

Neurocrine Biosciences Inc

EXEL

Exelixis, Inc.

Compare BSEM with

Compare BSEM with any company

Follow BSEM

Get an email when BioStem Technologies, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BSEM: get an email when it files

Where the numbers come from

Financial figures are the values BioStem Technologies, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.